Noubar Afeyan willing to use his potential to strengthen Armenia 

ArmInfo.Well-known entrepreneur, scientist, philanthropist, founder and director of Flagship Pioneering Noubar Afeyan expressed his readiness to use his capabilities and connections to strengthen the Motherland. He stated  this during a meeting with the Minister of High- Technological Industry of Armenia Mkhitar Hayrapetyan.

He also emphasized the importance of implementing scientific and  research-oriented programs for the development of the country.

The parties discussed the concept of creating an investment fund  within the framework of PPP (public- private partnership), noted the  need to increase the investment attractiveness of Armenia, and talked  about the participation of famous figures in the World Congress of  Information Technologies (WCIT), which will be held in October in  Yerevan.

Noubar Afeyan is founder and CEO of Flagship Pioneering. He is also  co-founder and Board Chairman of Moderna.

Founded in 2000, Flagship is an enterprise where  entrepreneurially-minded scientists invent seemingly unreasonable  solutions to challenges facing human health and sustainability. They  begin by asking "What if?" and iterate toward the unexpected answers  resulting in the creation of first-in-category bioplatform companies  with significant impact. Flagship has developed more than 100  scientific ventures resulting in over $100 billion in aggregate  value, thousands of patents and patent applications, and more than 50  drugs in clinical development.

During his career as inventor, entrepreneur, and CEO, Noubar has  cofounded and helped build over 70 life science and technology  startups. Prior to founding Flagship Pioneering, Noubar was the  founder and CEO of PerSeptive Biosystems, a leader in  bio-instrumentation that grew to $100 million in annual revenues.   After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in  1998, he became senior vice president and chief business officer of  Applera, where he initiated and oversaw the creation of Celera  Genomics.

In addition to his role at Moderna (NASDAQ: MRNA), the pioneering  messenger RNA medicines company, he is also co-founder and Board  Chairman of Generate:Biomedicines, Tessera Therapeutics, Alltrna,  Apriori Bio, and ProFound Therapeutics. Previously, he was a member  of the founding team, director, and investor in highly successful  ventures including Chemgenics Pharmaceuticals (acquired by Millenium  Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus  Therapeutics (acquired by Bristol-Myers Squibb), and Affinnova  (acquired by AC Nielsen).

Noubar entered biotechnology during its emergence as an academic  field and industry, completing his doctoral work in biochemical  engineering at MIT in 1987. He has written numerous scientific  publications and is the inventor of over 100 patents. He was a senior  lecturer at MIT's Sloan School of Management from 2000 to 2016, and a  lecturer at Harvard Business School until 2020. He teaches and speaks  around the world on topics ranging from entrepreneurship, innovation,  and economic development to biological engineering, new medicines,  and renewable energy.